Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program
This rule updates Medicare Part B payment policies and includes changes to coverage for certain drugs and biologicals, but does not directly address dietary supplement labeling or FDA requirements. No immediate impact on supplement businesses.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers should confirm how it applies to their specific situation before acting. There is a time constraint attached: N/A. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
No changes to dietary supplement labeling requirements; rule focuses on Medicare Part B payment and coverage policies.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers
What you must do
No action needed for supplement labeling compliance.
Deadline
N/A
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trial